VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients
Genetic testing and PARP inhibitors in metastatic prostate cancer
Breast cancer highlights from ASCO 2019
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer
CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC
Highlights from ASCO 2019
Potential of PARP inhibitors for metastatic breast cancer
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer